News Releases Keyword search Year None20212020201920182017201620152014201320122011201020092008 6/17/2021 AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials 6/1/2021 Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting 5/26/2021 Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting 5/20/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease 5/17/2021 AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results 5/13/2021 Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting 5/10/2021 AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021 5/6/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement 4/8/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure 3/31/2021 AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Print Page RSS Feeds
Keyword search Year None20212020201920182017201620152014201320122011201020092008 6/17/2021 AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials 6/1/2021 Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting 5/26/2021 Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting 5/20/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease 5/17/2021 AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results 5/13/2021 Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting 5/10/2021 AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021 5/6/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement 4/8/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure 3/31/2021 AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
6/17/2021 AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials
6/1/2021 Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting
5/26/2021 Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting
5/20/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease
5/13/2021 Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting
5/6/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement
4/8/2021 AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure
